72 patient multi-indication trial approved to fast track TRP-8803 commercialisation
- Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803
- Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework
- Study indications include Anorexia Nervosa, Body Dysmorphic...
Read more: 72 patient multi-indication trial approved to fast track TRP-8803 commercialisation




